ARTICLE | Clinical News
TLN-4601: Phase II discontinued
January 4, 2010 8:00 AM UTC
Thallion discontinued an open-label Phase II trial after a planned interim analysis showed that only 3 out of 17 evaluable patients treated with 480 mg/m 2/day IV TLN-4601 demonstrated stable disease ...